Health
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – March 16, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that new data demonstrating the prognostic value of the Genomic Prostate Score (GPS mdx) test across multiple treatment strategies were present
About this update from Mdxhealth Sa
[{"type":"image","alt":"mdxhealth","displaySize":"","headline":null,"caption":"mdxhealth","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sf2Nm0vg.EDhfYYAQ2giIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc","width":300,"height":44}},"lazy":false},{"type":"text","content":"Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026","length":175,"tagName":"p"},{"type":"text","content":"IRVINE, California – March 16, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that new data demonstrating the prognostic value of the Genomic Prostate Score (GPS mdx) test across multiple treatment strategies were presented on March 13th at the 41st Annual European Association of Urology (EAU) Congress, in London.","length":438,"tagName":"p"},{"type":"text","content":"The late-breaking abstract from the GPS-ProMPT study, led by investigators at the University of Oxford, highlighted how the GPS mdx assay identified patients with biologically indolent prostate cancer despite adverse clinical risk factors. The findings demonstrate how GPS mdx insights help personalize treatment decisions by identifying patients who may safely benefit from treatment de-escalation.","length":399,"tagName":"p"},{"type":"text","content":"The study was presented by Professor Freddie Hamdy, Nuffield Professor of Surgery and Professor of Urology at the University of Oxford, a globally recognized leader in prostate cancer research and one of the field’s most influential clinical investigators","length":255,"tagName":"p"},{"type":"text","content":"“This presentation represents the first major milestone in our research collaboration with the University of Oxford and is an important step forward as we advance the GPS-ProtecT study together. As we continue to build on the outstanding investigative work led by Professor Freddie Hamdy and his team at Oxford, we expect to generate some of the most meaningful clinical ...